Akebia’s Vafseo (Vadadustat) Tablets Gains the US FDA’s Approval to Treat Anemia Due to CKD

Share this

Akebia’s Vafseo (Vadadustat) Tablets Gains the US FDA’s Approval to Treat Anemia Due to CKD


  • The US FDA has approved the company’s Vafseo (vadadustat) tablets as a treatment of anemia associated with chronic kidney disease (CKD) in adults on dialysis for at least 3mos. The company, in collaboration with CSL Vifor, will commercialize Vafseo across the US   
  • The approval was based on the safety and efficacy results from INNO2VATE trial and an evaluation of safety outcomes after marketing in Japan. The results were published in the New England Journal of Medicine 
  • Vafseo (oral, QD) is a HIF-PH inhibitor that triggers the body's response to hypoxia by promoting the production of erythropoietin to address anemia 

Ref: Akebia | Image: Akebia

Related News:- Akebia Signs a License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG to Commercialize Vafseo for Anemia Associated with CKD

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions